RxDoctor Payments Data

Jerome Ramos-Esteban, MD

Ophthalmology · Concord, NHNPI 1366553398

Payments from drug & device makers

What this record shows

Alcon accounts for 63.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $2,805 and has fallen 91.3% since, to $245 in 2025.

$3,145in general payments, 2019–2025

Across 38 payments — averaging $82.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Amgen$464
  • AbbVie$284
  • Ocular Therapeutix, Inc.$121
  • Bausch & Lomb Americas Inc.$121
  • Carl Zeiss Meditec, Inc.$60
  • plus $92 from 2 others

What the payments were for

  • Travel & lodging$1,44746%
  • Food & beverage$1,69854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,145 in reported general payments places this provider in the 70th percentile of 80 ophthalmology providers in New Hampshire.

See all ophthalmology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$134,667
Medicare patients
673
Services billed
1,623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner22$41,582
RocklatanNetarsudil Mesylat/Latanoprost35$14,737
RestasisCyclosporine14$10,374
Cyclosporine20$10,051
LumiganBimatoprost13$5,801
SimbrinzaBrinzolamide/Brimonidine Tart21$5,609
Prednisolone Acetate120$4,165
Latanoprost394$3,446
Brimonidine Tartrate30$2,480
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$2,297
Travoprost17$2,125
Ketorolac Tromethamine70$1,209
ValacyclovirValacyclovir Hcl11$859
Ofloxacin77$846
Timolol Maleate25$685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$57$41,58222 claims
AbbVieRestasis, Lumigan$284$16,17527 claims
AlconSimbrinza$2,004$5,60921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 80 ophthalmology providers in New Hampshire.

Other ophthalmology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →